A Phase I clinical trial of a DC vaccine pulsed with Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitope for pancreatic cancer in combination with chemotherapy was reported. Here, WT1 is linked to familial pancreatic carcinoma.